Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R...

Related Keywords

California ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,San Diego ,American ,John Heymach ,Xiuning Le ,Mario Corso ,Guardant Health ,American Association Of Cancer Research ,Nasdaq ,Foundation Medicine Foundationinsights ,Exchange Commission ,Diamond Therapeutics Inc ,Company Masterkey ,Md Anderson Cancer Center ,Globenewswire Inc ,Diamond Therapeutics ,Cancer Research ,Annual Meeting ,Targeting Classical ,Resistance Mutation ,Evolved Landscape ,Foundation Medicine ,Neck Medical Oncology ,Associate Professor ,Chief Scientific Officer ,Private Securities Litigation Reform Act ,Annual Report ,States Securities ,Investor Relations ,Markets ,